Juno Therapeutics
Biotechnology company focused on developing cancer immunotherapies.
About
Juno Therapeutics was a biopharmaceutical company founded in 2013, focused on developing a pipeline of cancer immunotherapy drugs, particularly CAR-T and TCR therapies. It was acquired by Celgene in 2018 for $9 billion.
Similar companies
Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.
Shares Biotechnology, Pharmaceuticals
A clinical-stage dermatology company developing novel therapies for inflammatory skin diseases.
Shares Biotechnology, Pharmaceuticals
Genomics and AI-driven health intelligence company focused on extending healthy human life.
In HealthTech
Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.
Shares Biotechnology, Pharmaceuticals
Biotechnology company developing and commercializing cell therapies for cancer treatment.
Shares Biotechnology, Pharmaceuticals
Developing novel immunotherapies and diagnostics for cancer.
Shares Biotechnology, Immunotherapy
Key facts
- Headquarters
- Seattle, United States
- Founded
- 2013
- Total funding
- $317M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 5 Aug 2014 | Series B | $134M | |
| 24 Apr 2014 | Series A | $176M | Arch Venture Partners |
| 26 Dec 2013 | Series A | $7M |
Frequently asked
How much funding has Juno Therapeutics raised?
Juno Therapeutics has raised a total of $317M in funding. The most recent round on record is Series B.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Juno Therapeutics
